BIOSAFETY LEVEL 4 CORE
生物安全 4 级核心
基本信息
- 批准号:8642744
- 负责人:
- 金额:$ 51.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-03-01 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:AerosolsAgreementAngolaAnimal ModelAnimalsAntiviral AgentsArbovirusesBiological AvailabilityBioterrorismCase Fatality RatesCategoriesCaviaCell Culture TechniquesCenters for Disease Control and Prevention (U.S.)CollectionDemocratic Republic of the CongoDevelopmentDiagnosticDisease OutbreaksDoctor of PhilosophyDoseEbola virusEmergency SituationEmerging Communicable DiseasesEnzymesEquipmentEventFilovirusFrankfurt-Marburg Syndrome VirusFundingFutureGenetic TranscriptionGoalsGovernmentHousingHumanImageImmunityImmunologyIn VitroInfectionInfectious Diseases ResearchInstitutesInterferonsInvestigationLaboratoriesLeadMethodologyMethodsMissionModalityModelingMusNational Institute of Allergy and Infectious DiseaseOralPharmaceutical PreparationsPopulationPublic HealthResearchResourcesRodentRoleSafetySenior ScientistServicesStructureSudanSystemTestingTherapeuticToxic effectTrainingUnited States National Institutes of HealthVaccinationVaccinesViral Hemorrhagic FeversViral ProteinsVirusVirus DiseasesWorkZaire Ebola virusanaloganimal model developmentbasebiodefensebiosafety level 4 facilitybiothreatcareerdesignexperiencehemorrhagic fever virusin vitro activityin vivoinhibitor/antagonistlaboratory accidentmembernonhuman primatepathogenpre-clinicalprofessorscreeningsmall moleculetherapeutic targettissue processingvaccine candidatevaccine development
项目摘要
The CDC and NIAID have classified Ebola virus (EBOV) and Marburg virus (MARV) as Category A priority pathogens. EBOV and MARV cause severe and often fatal hemorrhagic fever in humans and nonhuman primates with case fatality rates up to 90% for some species or strains such as EBOV Zaire and MARV strain Angola. There are presently no approved active or passive therapeutic modalities for EBOV infections resulting from a natural outbreak, laboratory accident, or deliberate misuse. Therefore, identification of effective small molecule inhibitors of filoviral IFN-antagonists and of VP30 function that can be developed into drugs would be of high significance. The goal of this Center Is to develop small molecule anti-filoviral therapeutics that target filoviralinterferon (IFN) antagonist functions and VP30 function. Fundamental to this effort will be the testing of candidate compounds for antiviral activity against EBOV and MARV in cell culture and in animal models. Such testing must be performed at Biosafety Level 4 / Animal Biosafety level 4 (BSL- 4/ABSL-4) in accordance with Select Agent rules. The BSL4 core will first evaluate the antiviral activity of compounds identified by Projects 2 and 3 in cell culture. Lead inhibitors will be further evaluated In the mouse and guinea pig models of EBOV or MARV Infections to identify the best preclinical development candidates. Therefore, Core B will provide the proof of concept for the antiviral activities of hit compounds isolated In Projects 2 and 3. Moreover, Core B has an Important role in the hit to lead optimization. Its efforts together with the efforts from Projects 1, 2 and 3 will provide the relationships between analog structure and four key features - anti-filovirus activity, In vitro ADME including potential oral bioavailability, in vivo efficacy and safety. Further, an understanding of the MOA, as outlined in Projects 1 and 3, will be very Important In the design and future development of these first-in-class inhibitors by, for example, alleviating concerns about target-based toxicity.
CDC和NIAID已将埃博拉病毒(EBOV)和马尔堡病毒(MARV)列为A类优先病原体。埃博拉病毒和马里病毒在人类和非人类灵长类动物中引起严重且往往致命的出血热,某些物种或毒株(如扎伊尔埃博拉病毒和安哥拉马里病毒毒株)的病死率高达90%。对于由自然暴发、实验室事故或故意误用引起的EBOV感染,目前尚无批准的主动或被动治疗方式。因此,寻找丝状病毒ifn拮抗剂和VP30功能的有效小分子抑制剂并开发成药物具有重要意义。该中心的目标是开发针对丝状病毒干扰素(IFN)拮抗剂功能和VP30功能的小分子抗丝状病毒疗法。这项工作的基础将是在细胞培养和动物模型中测试候选化合物对EBOV和MARV的抗病毒活性。此类测试必须在生物安全等级4/动物生物安全等级4 (BSL- 4/ABSL-4)下按照选择制剂规则进行。BSL4核心将首先在细胞培养中评估项目2和项目3鉴定的化合物的抗病毒活性。铅抑制剂将在EBOV或MARV感染的小鼠和豚鼠模型中进一步评估,以确定最佳的临床前开发候选药物。因此,核心B将为项目2和项目3中分离的hit化合物的抗病毒活性提供概念证明。此外,核心B在hit to lead优化中发挥着重要作用。其与项目1、2和3的努力将提供类似物结构与四个关键特征之间的关系-抗丝状病毒活性,体外ADME(包括潜在的口服生物利用度),体内有效性和安全性。此外,如项目1和项目3所述,了解MOA对这些一流抑制剂的设计和未来开发非常重要,例如,减轻对靶向毒性的担忧。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander Bukreyev其他文献
Alexander Bukreyev的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander Bukreyev', 18)}}的其他基金
Molecular Mechanisms of the Dysregulated Immune Response to Ebola Virus
埃博拉病毒免疫反应失调的分子机制
- 批准号:
10394314 - 财政年份:2021
- 资助金额:
$ 51.74万 - 项目类别:
Research Project 1: Role of Epigenetic and Transcriptional Mechanisms in the Pathogenesis of Ebola Virus Disease
研究项目1:表观遗传和转录机制在埃博拉病毒疾病发病机制中的作用
- 批准号:
10602491 - 财政年份:2021
- 资助金额:
$ 51.74万 - 项目类别:
Molecular Mechanisms of the Dysregulated Immune Response to Ebola Virus
埃博拉病毒免疫反应失调的分子机制
- 批准号:
10602482 - 财政年份:2021
- 资助金额:
$ 51.74万 - 项目类别:
Research Project 1: Role of Epigenetic and Transcriptional Mechanisms in the Pathogenesis of Ebola Virus Disease
研究项目1:表观遗传和转录机制在埃博拉病毒疾病发病机制中的作用
- 批准号:
10188759 - 财政年份:2021
- 资助金额:
$ 51.74万 - 项目类别:
Research Project 1: Role of Epigenetic and Transcriptional Mechanisms in the Pathogenesis of Ebola Virus Disease
研究项目1:表观遗传和转录机制在埃博拉病毒疾病发病机制中的作用
- 批准号:
10394319 - 财政年份:2021
- 资助金额:
$ 51.74万 - 项目类别:
相似海外基金
A study for cross borders Indonesian nurses and care workers: Case of Japan-Indonesia Economic Partnership Agreement
针对跨境印度尼西亚护士和护理人员的研究:日本-印度尼西亚经济伙伴关系协定的案例
- 批准号:
22KJ0334 - 财政年份:2023
- 资助金额:
$ 51.74万 - 项目类别:
Grant-in-Aid for JSPS Fellows
NSF-NOAA Interagency Agreement (IAA) for the Global Oscillations Network Group (GONG)
NSF-NOAA 全球振荡网络组 (GONG) 机构间协议 (IAA)
- 批准号:
2410236 - 财政年份:2023
- 资助金额:
$ 51.74万 - 项目类别:
Cooperative Agreement
Conditions for U.S. Agreement on the Closure of Contested Overseas Bases: Relations of Threat, Alliance and Base Alternatives
美国关于关闭有争议的海外基地协议的条件:威胁、联盟和基地替代方案的关系
- 批准号:
23K18762 - 财政年份:2023
- 资助金额:
$ 51.74万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
MSI Smart Manufacturing Data Hub – Open Calls Grant Funding Agreement
MSI 智能制造数据中心 – 公开征集赠款资助协议
- 批准号:
900240 - 财政年份:2023
- 资助金额:
$ 51.74万 - 项目类别:
Collaborative R&D
Challenges of the Paris Agreement Exposed by the Energy Shift by External Factors: The Case of Renewable Energy Policies in Japan, the U.S., and the EU
外部因素导致的能源转移对《巴黎协定》的挑战:以日本、美国和欧盟的可再生能源政策为例
- 批准号:
23H00770 - 财政年份:2023
- 资助金额:
$ 51.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Continuation of Cooperative Agreement between U.S. Food and Drug Administration and S.C. Department of Health and Environmental Control (DHEC) for MFRPS Maintenance.
美国食品和药物管理局与南卡罗来纳州健康与环境控制部 (DHEC) 继续签订 MFRPS 维护合作协议。
- 批准号:
10829529 - 财政年份:2023
- 资助金额:
$ 51.74万 - 项目类别:
National Ecological Observatory Network Governing Cooperative Agreement
国家生态观测站网络治理合作协议
- 批准号:
2346114 - 财政年份:2023
- 资助金额:
$ 51.74万 - 项目类别:
Cooperative Agreement
The Kansas Department of Agriculture's Flexible Funding Model Cooperative Agreement for MFRPS Maintenance, FPTF, and Special Project.
堪萨斯州农业部针对 MFRPS 维护、FPTF 和特别项目的灵活资助模式合作协议。
- 批准号:
10828588 - 财政年份:2023
- 资助金额:
$ 51.74万 - 项目类别:
Robust approaches for the analysis of agreement between clinical measurements: development of guidance and software tools for researchers
分析临床测量之间一致性的稳健方法:为研究人员开发指南和软件工具
- 批准号:
MR/X029301/1 - 财政年份:2023
- 资助金额:
$ 51.74万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Linguistic transfer in a contact variety of Spanish: Gender agreement production and attitudes
博士论文研究:西班牙语接触变体中的语言迁移:性别协议的产生和态度
- 批准号:
2234506 - 财政年份:2023
- 资助金额:
$ 51.74万 - 项目类别:
Standard Grant